The National Comprehensive Cancer Network (NCCN) guidelines [4] recommend RRSO for ovarian cancer risk reduction by age 35-40 years for BRCA1 mutation carriers, and by age 40-45 years for BRCA2 variant carriers. This evidence concerns the gene BRCA2 and ovarian carcinoma.